Detailed narrative
Atera Launch and Capabilities
The company launched Atera, its new instrument platform, which is described as the most significant product introduction in its history. Atera enables spatial whole transcriptome analysis with single cell sensitivity at scale, processing up to 800 whole transcriptome 1 cm² samples per year or over 3,000 with targeted panels. It builds on the Xenium workflow, uses standard glass slides, and features powerful computational tools for efficient data processing, addressing historical trade-offs in spatial biology.
Extraordinary Customer Response to Atera
Customer reception to Atera has exceeded high expectations, with researchers calling it a 'technology leap' and the 'holy grail.' This enthusiasm is translating into strong pre-orders, with customers immediately focusing on integrating Atera into multi-year research programs and large cohort studies. The platform is seen as a 'must-have' despite a challenging capital equipment environment, with customers finding CapEx for its acquisition.
AI as a Structural Tailwind
AI is identified as a significant and structural tailwind for the business, driving demand for large amounts of high-quality biological data. Products like Flex Apex and Atera are designed to meet this need, with intense interest from customers building AI models. Partnerships with Chan Zuckerberg Initiative, Arc Institute, Xaira Therapeutics, and Bioptimus (for the STELA initiative) underscore the growing importance of AI-driven research and large-scale data generation.
Translational Applications and Clinical Evidence
There is growing interest in translational applications across academia and biopharma, with a focus on identifying human-relevant drug targets and biomarkers. Flex Apex and Xenium have proven valuable in these settings, and Atera is expected to extend this momentum by enabling larger studies with more information content. The company is pursuing internal efforts to generate clinical evidence for tissue-based spatial profiling in oncology and blood-based single cell monitoring in autoimmune disease.
Spatial Portfolio Strategy and Cannibalization
The company anticipates some customers may delay purchases of current Spatial products (Xenium, Visium) in anticipation of Atera, a dynamic factored into the full-year guidance. While Atera is expected to reinforce the trend towards imaging-based readouts and eventually attract more applications, existing platforms like Visium will continue to be used robustly for ongoing projects and established workflows due to their proven capabilities and customer loyalty.
Financial Performance and Operational Discipline
The company has significantly improved its operating profile over the past year, growing its cash balance by over $100 million despite a challenging macro environment. Gross margin improved due to lower warranty costs and inventory write-downs. Operating expenses decreased significantly year-over-year, reflecting disciplined cost management, with expectations for OpEx to be roughly flat year-on-year for FY26.